Last reviewed · How we verify
Part C - Safety expansion cohort in participants with axSpA
Part C - Safety expansion cohort in participants with axSpA is a Small molecule drug developed by Grey Wolf Therapeutics. It is currently in Phase 1 development.
At a glance
| Generic name | Part C - Safety expansion cohort in participants with axSpA |
|---|---|
| Sponsor | Grey Wolf Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part C - Safety expansion cohort in participants with axSpA CI brief — competitive landscape report
- Part C - Safety expansion cohort in participants with axSpA updates RSS · CI watch RSS
- Grey Wolf Therapeutics portfolio CI
Frequently asked questions about Part C - Safety expansion cohort in participants with axSpA
What is Part C - Safety expansion cohort in participants with axSpA?
Part C - Safety expansion cohort in participants with axSpA is a Small molecule drug developed by Grey Wolf Therapeutics.
Who makes Part C - Safety expansion cohort in participants with axSpA?
Part C - Safety expansion cohort in participants with axSpA is developed by Grey Wolf Therapeutics (see full Grey Wolf Therapeutics pipeline at /company/grey-wolf-therapeutics).
What development phase is Part C - Safety expansion cohort in participants with axSpA in?
Part C - Safety expansion cohort in participants with axSpA is in Phase 1.